A PHASE I/II TRIAL OF CYCLOPHOSPHAMIDE, CARFILZOMIB, THALIDOMIDE AND DEXAMETHASONE (CYCLONE) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

被引：0
|
作者：
Mikhael, J. [1 ]
Reeder, C. [1 ]
Libby, E. [2 ]
Costa, L. [3 ]
Mayo, A. [1 ]
Bergsagel, L. [1 ]
Buadi, F. [4 ]
Pirooz, N. [1 ]
Lubben, J. [1 ]
Dueck, A. [1 ]
Stewart, A. [1 ]
机构：
[1] Mayo Clin Arizona, Scottsdale, AZ USA
[2] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA
[3] Med Univ South Carolina, Charleston, SC 29425 USA
[4] Mayo Clin Rochester, Rochester, MN USA
来源：
HAEMATOLOGICA | 2012年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0295
引用
收藏
页码：119 / 119
页数：1
相关论文
共 50 条
  • [11] Phase II Trial of Syncopated Thalidomide, Lenalidomide, and Weekly Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
    Tufail, Madiha
    Siegel, David S.
    McBride, Laura
    Bilotti, Elizabeth
    Bello, Erica
    Anand, Palka
    Olivo, Karly
    Bendarz, Urszula
    McNeill, Ann
    Vesole, David H.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2012, 12 (03): : 186 - 190
  • [12] Phase II study of carfilzomib and dexamethasone therapy for newly diagnosed multiple myeloma
    Forsberg, Peter A.
    Rossi, Adriana C.
    Boyer, Angelique
    Tegnestam, Linda
    Pearse, Roger N.
    Perry, Arthur
    Pekle, Karen A.
    Jayabalan, David
    Ely, Scott
    Boussi, Leora
    Sherbenou, Daniel W.
    Willianns, Colt
    Allan, John N.
    Coleman, Morton
    Niesvizky, Ruben
    Mark, Tomer M.
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (05) : 539 - 545
  • [13] CYCLOPHOSPHAMIDE, THALIDOMIDE AND DEXAMETHASONE (CTD) AS INITIAL THERAPY FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
    Vasquez, J.
    Ruiz, R.
    Aliaga, K.
    Valencia, F.
    Enriquez, D.
    Palacios, V.
    Quintana, S.
    Casanova, L.
    HAEMATOLOGICA, 2016, 101 : 798 - 798
  • [14] Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma
    Sonneveld, Pieter
    Asselbergs, Emilie
    Zweegman, Sonja
    van der Holt, Bronno
    Kersten, Marie Jose
    Vellenga, Edo
    van Marwijk-Kooy, Marinus
    Broyl, Annemiek
    de Weerdt, Okke
    Lonergan, Sarah
    Palumbo, Antonio
    Lokhorstl, Henk
    BLOOD, 2015, 125 (03) : 449 - 456
  • [15] Phase II trial of lenalidomide, cyclophosphamide, and dexamethasone (CRd) for newly diagnosed myeloma
    Kumar, Shaji
    Hayman, Suzanne R.
    Buadi, Francis K.
    Lacy, Martha Q.
    Stewart, Keith
    Greipp, Philip R.
    Russell, Stephen
    Zeldenrust, Steven
    Gertz, Morie A.
    Bergsagel, Leif
    Fonseca, Rafael
    Allred, Jacob
    Campbell, Megan
    Lust, John A.
    Witzig, Thomas E.
    Kyle, Robert A.
    Rajkumar, S. Vincent
    Dispenzieri, Angela
    BLOOD, 2007, 110 (11) : 64A - 64A
  • [16] Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial
    Wester, Ruth
    van der Holt, Bronno
    Asselbergs, Emelie
    Zweegman, Sonja
    Kersten, Marie Jose
    Vellenga, Edo
    Kooy, Marinus van Marwijk
    de Weerdt, Okke
    Minnema, Monique
    Lonergan, Sarah
    Palumbo, Antonio
    Lokhorst, Henk
    Broijl, Annemiek
    Sonneveld, Pieter
    HAEMATOLOGICA, 2019, 104 (11) : 2265 - 2273
  • [17] Cyclophosphamide, thalidomide and dexamethasone (CTD) as initial therapy for newly diagnosed multiple myeloma patients.
    Chavez, Jule Franve Vasquez
    Mendoza, Rossana Esther Ruiz
    Llerena, Karina Mayra Aliaga
    Valencia, Fernando
    Enriquez, Daniel
    Palacios, Victor
    Casanova, Luis
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [18] Efficacy and safety of thalidomide and dexamethasone combination with or without cyclophosphamide in patients with newly diagnosed multiple myeloma
    Kim, Y.-K.
    Lee, J. J.
    Sohn, S. K.
    Shin, H. J.
    Lee, S. R.
    Shim, H. J.
    Ahn, J. S.
    Kim, D. H.
    Yang, D. H.
    Cho, S. H.
    Chung, I. J.
    Kim, H. J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 411 - 412
  • [19] An Open-Label Phase I/II Study of Carfilzomib, Bendamustine and Dexamethasone (CBD) in Newly Diagnosed Multiple Myeloma Patients
    Leng, Siyang
    Raza, Shahzad
    Assal, Amer
    Baliko, Gregory
    Gould, Julia
    Shields, Rachel K.
    Mapara, Markus Y.
    Lentzsch, Suzanne
    BLOOD, 2017, 130
  • [20] Weekly Carfilzomib, Cyclophosphamide and Dexamethasone (wCCyd) in Elderly Newly Diagnosed Multiple Myeloma Patients: Results of a Phase 2 Study
    Bringhen, Sara
    Rossi, Davide
    Larocca, Alessandra
    Corradini, Paolo
    Galieni, Piero
    Malfitano, Alessandra
    Aschero, Simona
    Offidani, Massimo
    Liberati, Anna Marina
    Genuardi, Mariella
    Gaidano, Gianluca
    Palladino, Carmela
    Gentilini, Fabiana
    Boccadoro, Mario
    Sonneveld, Pieter
    Palumbo, Antonio
    BLOOD, 2015, 126 (23)
12345